Patient leaflets and SmPCs, drug interaction checker, official and paediatric dosages, pregnancy and breastfeeding guidance, and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official and paediatric dosages, pregnancy and breastfeeding guidance, and NHS pharmacy opening hours — all in one place.
Hayeeze eye drops are used for the treatment of signs and symptoms of seasonal allergic conjunctivitis, or hayfever, in adults. eye Hayeeze drops work by stopping release of substances in your eyes that can lead to an allergic reaction and cause symptoms such as itchy, watery, red, or inflamed eyes.
Warnings and precautions Talk to your doctor or pharmacist before using Hayeeze eye drops.
Stop using Hayeeze eye drops if no improvement or if worsening of the symptoms is observed within 48 hours. In such case, refer to your doctor immediately.
You should remove contact lenses that are in your eyes before using eye drops. Hayeeze
You should consult your doctor before using Hayeeze eye drops if you have dry eyes or conditions where the cornea may be compromised.
Other medicines and Hayeeze eye drops Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
If you are using other eye drops or eye ointment medicines, leave at least 5 minutes between each medicine. Eye ointments should be administered last.
Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. You should not use Hayeeze eye drops if you are breast- eeding, ask your f doctor for advice before using this medicine.
Driving and using machines You may find that your vision is blurred for a time just after you use Hayeeze eye drops. Do not drive or use machines until this has worn off.
Hayeeze eye drops contain benzalkonium chloride This medicine contains 0.5 mg benzalkonium chloride in each 5 ml which is equivalent to 0.1 mg/ml. Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. You should remove contact lenses before using this medicine and put them back 15 minutes afterwards. Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.
Hayeeze eye drops contain Disodium Phosphate Dodecahydrate This medicine contains 16.7 mg phosphates (in 63.05 mg disodium phosphate dodecahydrate) in each bottle of 5 ml, which is equivalent to 3.34 mg/ml. If you suffer from severe damage to the clear layer at the front of the eye (the cornea), phosphates may cause in very rare cases cloudy patches on the cornea due to calcium build-up during treatment.
The recommended dose is one drop in the eye or eyes, twice a day, morning and evening. Do not use more medicine or more often than recommended. Only use Hayeeze eye drops as an eye drop.
Instructions on using Hayeeze eye drops Get the Hayeeze eye drops bottle and a mirror. Wash your hands. Take the bottle and twist offthe cap. After cap is removed, if the tamper evident snap collar is loose, remove before using the product. Hold the bottle, pointing down, between your thumb and middle finger. Tilt your head back. Pull down your eyelid with a clean finger, until there is a 'pocket between the eyelid and your eye. The drop will go in here.
Bring the bottle top close to the eye. Use the mirror if it helps. Don't touch your eye or eyelid, surrounding areas or other surfaces with the dropper. It could infect the drops left in the bottle. Gently press on the base of the bottle to release one drop of Hayeeze eye drops at a time. Don't squeeze the bottle, it is designed so that just a gentle press on the bottom is needed.
If you use drops in both eyes, repeat the steps for your other eye. Put the bottle cap back on firmly immediately after use. Use up one bottle before opening the next bottle. If a drop misses your eye, try again.
If you use more Hayeeze eye drops than you should Rinse it all out with warm water. Don't put in any more drops until it's time for your next regular dose.
If you forget to use Hayeeze eye drops Use a single drop as soon as you remember, and then go back to your regular routine. However, if it is almost time for your next dose, skip the missed dose before going back to your regular dosing routine. Do not use a double dose to make up for the one missed.
If you stop using Hayeeze eye drops Stop using Hayeeze eye drops if no improvement is observed within 48 hours. In such case, refer to your doctor immediately.
4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop using Hayeeze eye drops and see a doctor straight away, if you notice any of the following serious side effects: H . The signs may include: skin ypersensitivity itching or rash, swelling of the face, lips, tongue, body or breathing difficulties, Corneal effects (damage to the clear layer at the front of the eye). The signs may include pain, superficial erosions of the cornea, cloudy patches, redness of the eye, blurred vision, sensitivity to light, watery eye.
Common (may affect up to 1 in 10 people) Effects in the eye: eye pain, eye irritation, dry eye, abnormal eye sensation, eye discomfort.
General side effects: headache, fatigue, dry nose, bad taste.
Uncommon (may affect up to 1 in 100 people) Effects in the eye: blurred, reduced, or abnormal vision, corneal disorder, eye surface inflammation with or without surface damage, inflammation or infection of the conjunctiva, eye discharge, sensitivity to light, increased tear production, itchy eye, redness of the eye, eyelid abnormality, itching, redness, swelling, or crusting of the eyelid.
General side effects: abnormal or decreased sensation, dizziness, runny nose, dry skin, skin inflammation.
Not known (frequency cannot be estimated from the available data) Effects in the eye: eye swelling, corneal swelling, change in pupil size.
General side effects: shortness of breath, increased allergic symptoms, facial swelling, drowsiness, generalized weakness, nausea, vomiting, sinus infection, skin redness and itching.
In very rare cases, some patients with severe damage to the clear layer at the front of the eye (the cornea) have developed cloudy patches on the cornea due to calcium build-up during treatment.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.
Do not use this medicine after the expiry date which is stated on the label (EXP). The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
You must throw away the bottle four weeks after you first opened it, to prevent infections, and use a new bottle. Write down the date you opened it in the space on each bottle label.
Do not use this medicine if you notice a change in colour or smell. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Hayeeze eye drops look like and contents of the pack Clear to almost clear colourless solution, practically free from particles. 5 ml opaque low density polyethylene (LDPE) bottle with LDPE dropper and high density polyethylene (HDPE) tamper-proof screw-cap.
Pack sizes: 1 x 5 ml (1 bottle, which contains 5 ml of solution).
Marketing Authorisation Holder DAWA Ltd, 5 Sandridge Close, Harrow, Middlesex, HA1 1XD, UK.
Manufacturer actrevo GmbH, Großer Burstah 25, 20457 Hamburg Germany , .
D Ltd rugsrus , 5 Sandridge Close, Harrow, Middlesex, HA1 1XD, United Kingdom.
This leaflet was last revised in J . anuary 2024
Detailed information on this medicine is available on the website of www.mhra.gov.uk
Blind or partially sighted? Is this leaflet hard to see or read? Call 020 8423 2111 to obtain the leaflet in a format suitable for you. 02 9/L - 5 -HAY 3
Hayeeze 1 mg/ml Eye drops Solution comes as drops containing 1 mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Hayeeze 1 mg/ml Eye drops Solution is olopatadine hydrochloride.
Medicines with the same active substance include: OPATANOL 1mg/ml eye drops solution, Olopatadine 1 mg/ml Eye drops, Solution. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Hayeeze 1 mg/ml Eye drops Solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis in adults.
Posology
The dose is one drop of Olopatadine eye drops in the conjunctival sac of the affected eye(s) twice daily (8 hourly). Treatment may be maintained for up to four months, if considered necessary.
If symptoms do not improve or if they worsen within 48 hours, the drops should be discontinued, and a doctor consulted.
Use in elderly
No dosage adjustment in elderly patients is necessary.
Paediatric patients
Olopatadine eye drops should not be used in paediatric patients.
Use in hepatic and renal impairment
Olopatadine in the form of eye drops has not been studied in patients with renal or hepatic disease. However, no dosage adjustment is expected to be necessary in hepatic or renal impairment (see section 5.2).
Method of administration
For ocular use only.
After the bottle cap is removed, if the tamper evident snap collar is loose, remove before using the product. To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas, or other surfaces with the dropper tip of the bottle. Keep the bottle tightly closed when not in use.
In case of concomitant therapy with other topical ocular medicines, an interval of five minutes should be allowed between successive applications. Eye ointments should be administered last.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
In children and adolescents under the age of 18 years.
No interaction studies with other medicinal products have been performed.
In vitro studies have shown that olopatadine did not inhibit metabolic reactions which involve cytochrome P-450 isozymes 1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4. These results indicate that olopatadine is unlikely to result in metabolic interactions with other concomitantly administered active substances.
Pregnancy
There are no or limited amount of data from the use of ophthalmic olopatadine in pregnant women. Studies in animals have shown reproductive toxicity following systemic administration (see section 5.3). Olopatadine is not recommended during pregnancy and in women of childbearing potential not using contraception.
Breast-feeding
Available data in animals have shown excretion of olopatadine in milk following oral administration (for details see section 5.3). A risk to the newborn/infants cannot be excluded.
Olopatadine should not be used during breast-feeding.
Fertility
Studies have not been performed to evaluate the effect of topical ocular administration of olopatadine on human fertility.
Olopatadine has no or negligible influence on the ability to drive and use machines.
As with any eye drop, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machinery.
No data are available in humans regarding overdose by accidental or deliberate ingestion.
Olopatadine has a low order of acute toxicity in animals. Accidental ingestion of the entire contents of a bottle of Olopatadine would deliver a maximum systemic exposure of 5 mg olopatadine. This exposure would result in a final dose of 0.5 mg/kg in a 10 kg infant, assuming 100% absorption.
Prolongation of the QTc interval in dogs was observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. A 5 mg oral dose was administered twice-daily for 2.5 days to 102 young and elderly male and female healthy volunteers with no significant prolongation of QTc interval compared to placebo. The range of peak steady-state olopatadine plasma concentrations (35 to 127 ng/ml) seen in this study represents at least a 70-fold safety margin for topical olopatadine with respect to effects on cardiac repolarisation.
In the case of overdose, appropriate monitoring and management of the patient should be implemented.
Ask anything about Hayeeze 1 mg/ml Eye drops Solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.